New non-invasive AI microscope tracks blood clots before they become deadly

Artificial intelligence (AI) technology has the potential to revolutionize the way potentially deadly blood clots are detected before they strike. Scientists at the University of Tokyo have developed a non-invasive method to observe clotting activity in blood as it occurs, using a powerful microscope and AI tool.

Platelets, tiny blood cells that play a crucial role in heart disease, particularly coronary artery disease, are monitored in real-time using this new technology. Dr. Kazutoshi Hirose, the lead author of the study, emphasized the importance of monitoring platelet activity in individuals, especially those at risk of dangerous clots.

The traditional methods of monitoring platelet activity often involve indirect measurements or invasive procedures. However, the AI tool developed by the researchers allows for direct observation of platelets in the bloodstream and real-time measurement of their interactions and clumping.

The high-powered microscope functions like a super-high-speed camera, capturing thousands of images of blood cells in motion every second. Artificial intelligence is then used to analyze these images, distinguishing between single platelets, clumps of platelets, and other blood cells.

In a study involving over 200 patients, the researchers found that individuals with more severe heart problems exhibited more clumping in their blood. The results obtained from a blood sample taken from a patient’s arm using the AI tool were comparable to those obtained from blood taken directly from the heart’s arteries.

The implications of this technology for patient care are significant, as it could potentially change the standard of care for patients with coronary heart disease. The ability to monitor platelet activity in real-time could lead to safer and more personalized treatments for individuals at risk of blood clots.

However, there are still limitations to the widespread use of this technology, as the microscope is currently considered cutting-edge research equipment and not yet a bedside device. Further research is needed to miniaturize and reduce the cost of the technology before it can be widely implemented in clinical settings.

Looking ahead, experts envision a future where point-of-care analyzers equipped with AI technology could allow for quick and safe adjustments to antiplatelet drugs and other treatments based on real-time monitoring of platelet activity. This innovation has the potential to transform patient care and improve outcomes for individuals at risk of deadly blood clots.